Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder

被引:0
作者
Yuma Takeda
Noritoshi Kobayashi
Takaomi Kessoku
Naoki Okubo
Akihiro Suzuki
Motohiko Tokuhisa
Haruo Miwa
Naoko Udaka
Yasushi Ichikawa
机构
[1] Yokohama City University School of Medicine Graduate School of Medicine,Department of Oncology
[2] Yokohama City University Hospital,Department of Palliative Medicine
[3] Yokohama City University School of Medicine Graduate School of Medicine,Department of Gastroenterology and Hepatology
[4] Yokohama City University Medical Center,Gastroenterological Center
[5] Yokohama City University Hospital,Department of Pathology
来源
Clinical Journal of Gastroenterology | 2022年 / 15卷
关键词
Neuroendocrine tumor; Neuroendocrine carcinoma; Gallbladder; Chemoradiotherapy; Complete response;
D O I
暂无
中图分类号
学科分类号
摘要
Neuroendocrine carcinoma (NEC) is a rare subtype of malignant gallbladder tumor. Although surgical resection is the only potentially curative therapy for gallbladder NEC, most cases are surgically unresectable because of advanced stage disease and/or biologically aggressive behavior. The standard palliative treatment for malignant gallbladder tumors is chemotherapy; however, the efficacy of chemoradiotherapy in the treatment of gallbladder tumors is controversial. Here, we report a case of gallbladder NEC that showed a durable response to chemoradiotherapy. A 68-year-old Japanese man presented with a huge gallbladder tumor with liver and duodenal invasion. Pathological findings revealed poorly differentiated NEC of the gallbladder. After seven cycles of chemotherapy comprising cisplatin and irinotecan, computed tomography (CT) revealed remarkable tumor shrinkage, but an enlarged portal lymph node. The patient was treated with 50.4 Gy in 28 fractions with two cycles of cisplatin and etoposide. After chemoradiotherapy, the enlarged lymph node also decreased in size. Maximum standardized uptake value of fluorodeoxyglucose-positron emission tomography/CT(FDG-PET/CT) changed from 8.2 to physiological accumulation. We defined this condition as a complete response on both enhanced CT and FDG-PET/CT; therefore, we did not perform systemic treatment and only observed his condition. This patient remained healthy with no recurrence at 3 years after chemoradiotherapy.
引用
收藏
页码:803 / 808
页数:5
相关论文
共 39 条
  • [1] Hauso O(2008)Neuroendocrine tumor epidemiology: contrasting Norway and North America Cancer 113 2655-2664
  • [2] Gustafsson BI(2008)One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 3063-3072
  • [3] Kidd M(2020)WHO classification of tumours editorial board; for the WHO classification of tumours editorial board Histopathology 76 182-188
  • [4] Yao JC(2011)Neuroendocrine tumors of the gallbladder: a case report and review of the literature J Med Case Rep 5 334-970
  • [5] Hassan M(2011)Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours Dig Liver Dis 43 965-146
  • [6] Phan A(2005)Neuroendocrine carcinoma of gallbladder: report of 2 cases Hepatobiliary Pancreat Dis Int 4 144-695
  • [7] Nagtegaal ID(2010)Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy J Clin Gastroenterol 44 687-383
  • [8] Odze RD(2009)Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the surveillance, epidemiology, and end results program Ann Diagn Pathol 13 378-860
  • [9] Klimstra D(2020)Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 31 844-1044
  • [10] Mezi S(2021)JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis J Gastroenterol 56 1033-v37